Angle Regulatory News (AGL)

ANGLE plc ("the Company")

INVESTOR WEB CAST

Date : Friday 7 October @ 09:00am (BST)

Parsortix Update

VALIDATION FOR CANCER CELL ISOLATION TECHNOLOGY

ANGLE plc (AIM : AGL) was delighted to announce last week that Parsortix Inc ("Parsortix"), its 85% owned portfolio company which specialises in medical diagnostics had achieved a major milestone by validating that its cell separation device can capture cancer cells added to blood (please see announcement from 28 September).

In light of the market's extremely positive reaction to this significant development and investor requests to understand more about the Parsortix's patented cell separation device, ANGLE will be holding an investor webcast on Friday 7 October.

This live audio webcast will consist of a short presentation providing an overview of the Parsortix technology and how it works together with its potential commercial applications. The presentation will be given by Andrew Newland, ANGLE's CEO and Shane Booth, CEO of Parsortix.

To most efficiently manage this webcast those participants wishing to ask questions will be able to do so by sending their questions through Buchanan's "Mediaserve" portal once they have logged on. Questions will then be answered by ANGLE at the end of the presentation. There will also be a listen only dial-in facility for those that do not have access to the internet.

Webcast & Dial-in Details

Please log on 10 minutes before the start of the webcast (08:50am). The address is:

http://mediaserve.buchanan.uk.com/2011/angle071011/registration.asp

Once registered, there will be an option to send a question to ANGLE's management. To use the dial-in facility please call: +44 (0)20 3059 5702. The Participant Pass code is: 223399.

A recording of the webcast will also be made available on ANGLE's website.

ANGLE Founder and Chief Executive, Andrew Newland, commented:

"We look forward to updating investors on these recent findings. As commented last week, our view is that the Parsortix's cancer diagnostic has the potential to meet a key medical requirement and offers an outstanding commercial opportunity for ANGLE."

For further information: